Seelos Therapeutics Inc
NASDAQ:SEEL
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    3.9050
  • TODAY'S CHANGE (%)
    -1.0950 (-21.9000%)
  • Bid / Lots
    3.9000/ 57
  • Ask / Lots
    3.9100/ 1
  • Open / Previous Close
    3.8000 / 5.0000
  • Day Range
    3.7100
    4.5700
  • 52 Week Range
    2.9040
    848.6400
  • Volume
    1,292,873

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

  • Yesterday

      Show headlines and story abstract

    • 4:05PM ET on Thursday Sep 26, 2024 by PR Newswire
      Companies Mentioned: SEEL

      Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was originally scheduled to be held on September 27, 2024, has been postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/SEEL2024, on Friday, October 25, 2024 at 8:00 a.m., Eastern Time. The record date for the Annual Meeting August 19, 2024, is unchanged and applies to the postponed Annual Meeting.

    • 4:05PM ET on Thursday Sep 26, 2024 by Dow Jones
      Companies Mentioned: SEEL

      Seelos Announces Postponement of its Annual Meeting of Stockholders

      PR Newswire

      NEW YORK, Sept. 26, 2024

      NEW YORK, Sept. 26, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was originally scheduled to be held on September 27, 2024, has been postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/SEEL2024, on Friday, October 25, 2024 at 8:00 a.m., Eastern Time. The record date for the Annual Meeting August 19, 2024, is unchanged and applies to the postponed Annual Meeting.

Peers Headlines